NCT04953143: LiverPal

LiverPAL: A Pilot Study of Inpatient Palliative Care for Patients With Advanced Liver Disease

Completed NA Last updated 27 June 2023

What this trial tests

NA trial testing LiverPal Intervention in Cirrhosis, Liver in 25 participants. Completed in 16 August 2022.

Timeline

14 January 2022

Primary endpoint
16 August 2022

16 August 2022

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	25
Start date	14 January 2022
Primary completion	16 August 2022
Estimated completion	16 August 2022
Sites	1 location across United States

Drugs / interventions tested

• LiverPal Intervention

Conditions studied

• Cirrhosis, Liver — all drugs for Cirrhosis, Liver →

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Cirrhosis, Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Frequently patients with advanced liver disease experience physical and emotional symptoms during their hospitalization that can may cause a level of discomfort to both the patient and the family members that surround them.

This study involves the early introduction of a team of clinicians that specialize in the lessening (palliation) of many of these discomforting symptoms. This team of clinicians is called the palliative care team and they focus on ways to improve pain and other symptom management and to assist patients and their families in coping with the physical, emotional and social issues associated with a diagnosis of advanced liver disease. The team consists of physicians and advance practice nurses who have been specially trained in the care of patients facing serious illness and their caregivers.

The investigators are studying the feasibility of delivering this program, the acceptability and satisfaction with the program, and changes in the quality of life, illness understanding, and symptoms of hospitalized patients who receive the program and their caregivers. The study will use a series of questionnaires to measure the study participants' quality of life, physical symptoms, illness and prognostic understanding, and mood. Study questionnaires will be completed in the hospital, home or clinic. Qualitative interviews will be conducted with hepatology and palliative care clinicians as well as patients and caregivers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.